Hidradenitis Suppurativa Treatments Show Promise
New clinical trial data revealed three experimental therapies effectively targeted inflammatory pathways for the skin disease.
Updated on Oct. 3, 2026 in Diseases — General
Live Poll
Do you trust that new medical treatments will improve long-term outcomes for chronic skin conditions?
Researchers presented phase 2 results at the EADV 2026 Congress demonstrating the efficacy of tulisokibart, abdakibart, and lutikizumab. These treatments target specific cytokines associated with hidradenitis suppurativa to reduce disease symptoms in patients.
Why it matters
Hidradenitis suppurativa is driven by elevated neutrophil counts and cytokine expression in skin lesions, which these therapies aim to mitigate. The successful phase 2 results provide a potential path toward new clinical treatment standards.
Clinical trials measured treatment response in 149 patients for tulisokibart, 167 for the LOTUS trial of abdakibart, and 153 for lutikizumab. Lutikizumab demonstrated an 81.3% reduction in IL-1 beta expression in lesional skin.
The players
EADV 2026 Congress
This annual scientific event in Vienna brings together international dermatologists and researchers to share advancements in skin health.
The details
Tulisokibart and abdakibart function as monoclonal antibodies designed to block specific inflammatory cytokines, while lutikizumab lowers neutrophil counts and pathogenic fibroblast activity. These interventions specifically address the extracellular matrix remodeling that occurs within lesional skin.
Timeline
The EADV 2026 Congress took place in Vienna in 2026.
Tulisokibart treatment response curves separated from placebo by Week 4.
Clinical response endpoints were measured for tulisokibart and abdakibart at Week 16.
The Big Picture
This research represents a shift within the phase 2 clinical development pipeline for monoclonal antibodies. The trial results mark a departure from conventional broad-spectrum treatments by validating the efficacy of targeted cytokine inhibition.
These results indicate that future therapeutic options may offer improved symptom management and reduced skin inflammation for patients. Patients should consult their dermatologists regarding the progression of these treatments into phase 3 clinical trials.
The takeaway
Targeting specific cytokines like IL-1 beta and TL1A has proven effective in reducing inflammation in hidradenitis suppurativa. These developments suggest that personalized biological therapies could become a primary focus for managing severe chronic skin diseases.
Further reading
Learn more about the latest innovations in Diseases — General.
Source note: This article includes information reported by Medscape.
Live Poll
Do you trust that new medical treatments will improve long-term outcomes for chronic skin conditions?
